A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates (INTENSIFY)
A Multicenter Prospective Non-interventional Study Investigating the Treatment Effect of Xultophy® Intensification in a Real World Population With Type 2 Diabetes in United Arab Emirates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
AbuDhabi, United Arab Emirates
- Novo Nordisk Investigational Site
-
Ajman, United Arab Emirates, 4184
- Novo Nordisk Investigational Site
-
Dubai, United Arab Emirates
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- The decision to initiate treatment with commercially available Xultophy® has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study.
- Male or female, age greater than or equal to 18 years at the time of signing informed consent.
- Diagnosed with type 2 diabetes and treated with basal insulin plus or minus oral anti-diabetic drugs (OADs) or Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) plus or minus OADs, except Xultophy®, for at least 12 weeks prior to informed consent and initiation visit (visit 1).
- Available and documented glycosylated haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of Xultophy® treatment.
Exclusion Criteria:
- Hypersensitivity to the active substance or to any of the excipients as specified in the Xultophy® local label.
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Female who is known pregnant, breast-feeding or intends to become pregnant.
- Treated with Xultophy® previously.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients with type 2 diabetes (T2DM)
Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
|
Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)
Time Frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
|
Measured in % point
|
From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients reached HbA1c less than 7% at end of study (Yes/No )
Time Frame: At the end of study visit (26-34 weeks)
|
Number of patients who achieved/not achieved HbA1c at end of study: <7.0%
|
At the end of study visit (26-34 weeks)
|
|
Change in laboratory measured fasting plasma glucose (FPG)
Time Frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
|
Measured in mg/dL
|
From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
|
|
Average dose step of Xultophy® at end of the study
Time Frame: At the end of study (26-34 weeks)
|
Measured in dose steps/day
|
At the end of study (26-34 weeks)
|
|
Change of body weight
Time Frame: From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
|
Measured in kg
|
From baseline [≤12 weeks prior to treatment initiation [week 0]) to end of study (26-34 weeks)
|
|
Change in number of patient self-reported overall non-severe hypoglycaemic episodes based on recollection
Time Frame: Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 4 weeks prior to initiation of treatment with Xultophy® and to within 4 weeks prior to end of study (26-34 weeks)
|
Number of episodes
|
Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 4 weeks prior to initiation of treatment with Xultophy® and to within 4 weeks prior to end of study (26-34 weeks)
|
|
Change in number of patient self-reported nocturnal non-severe hypoglycaemic episodes based on recollection
Time Frame: Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 4 weeks prior to initiation of treatment with Xultophy® and to within 4 weeks prior to end of study (26-34 weeks)
|
Number of episodes
|
Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 4 weeks prior to initiation of treatment with Xultophy® and to within 4 weeks prior to end of study (26-34 weeks)
|
|
Change in number of patient self-reported severe hypoglycaemic episodes based on recollection (overall)
Time Frame: Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 26 weeks prior to initiation of treatment with Xultophy® and to within 26 weeks prior to end of study (26-34 weeks)
|
Number of episodes
|
Pre- to post- initiation of treatment with Xultophy®. Episodes occurring within 26 weeks prior to initiation of treatment with Xultophy® and to within 26 weeks prior to end of study (26-34 weeks)
|
|
Reason(s) for discontinuing treatment with Xultophy® during the treatment period, if applicable
Time Frame: At the end of study (26-34 weeks)
|
Pre-specified response option(s)
|
At the end of study (26-34 weeks)
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN9068-4458
- U1111-1213-4338 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.